SEC Comment Letter 0000000000-23-012602 to Tarsus Pharmaceuticals, Inc. (TARS) (CIK 0001819790) (TARS)
Tarsus Pharmaceuticals, Inc. (TARS) (CIK 0001819790)
Date: Nov. 16, 2023 · CIK: 0001819790 · Accession: 0000000000-23-012602
AI Filing Summary & Sentiment
File numbers found in text: 333-275439
Letter
United States securities and exchange commission logo November 16, 2023 Bobak Azamian, M.D., Ph.D. Chief Executive Officer Tarsus Pharmaceuticals, Inc. 15440 Laguna Canyon Road, Suite 160 Irvine, CA 92618 Re:Tarsus Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed November 9, 2023 File No. 333-275439 Dear Bobak Azamian: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tyler Howes at 202-551-3370 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Ryan Gunderson, Esq.
Show Raw Text
United States securities and exchange commission logo
November 16, 2023
Bobak Azamian, M.D., Ph.D.
Chief Executive Officer
Tarsus Pharmaceuticals, Inc.
15440 Laguna Canyon Road, Suite 160
Irvine, CA 92618
Re:Tarsus Pharmaceuticals, Inc.
Registration Statement on Form S-3
Filed November 9, 2023
File No. 333-275439
Dear Bobak Azamian:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tyler Howes at 202-551-3370 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Ryan Gunderson, Esq.